Studies have shown that Sox9 is overexpressed in osteosarcoma tissues compared to noncancerous bone tissues, and its high expression is associated with advanced clinical stages, positive distant metastasis, and poor response to chemotherapy. Here, SOX9 is linked to osteosarcoma.